Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro

Bioelectrochemistry

Volumn 71, Issue 2, 2007, Pages 113-117

  Bicek, Ajda ^a   Turel, Iztok ^a   Kanduser, Masa ^a   Miklavcic, Damijan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

B16F1; Electrochemotherapy; Electroporation; In vitro; NAMI A

Indexed keywords

B16F1; ELECTROCHEMOTHERAPY; ELECTROPORATION; IN VITRO; NAMI-A;

DRUG DELIVERY; LIVING SYSTEMS STUDIES; ONCOLOGY; RATS; RUTHENIUM COMPOUNDS;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; DIMETHYL SULFOXIDE; IMIDAZOLE DERIVATIVE; NAMI A; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL SUSPENSION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; ELECTROPORATION; IN VITRO STUDY; MELANOMA; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DIMETHYL SULFOXIDE; ELECTROCHEMOTHERAPY; ELECTROPORATION; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS;

EID: 35348892611     PISSN: 15675394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bioelechem.2007.05.002     Document Type: Article

References (26)

1. Mir L.M., and Orlowski S. Mechanisms of electrochemotherapy. Adv. Drug Deliv. Rev. 35 (1999) 107-118
2. Neumann E. The relaxation hysteresis of membrane electroporation. In: Neumann E., Sowers A.E., and Jordan C.A. (Eds). Electroporation and Electrofusion in Cell Biology (1989), Plenium Press, New York 61-82
3. Rols M.P., and Teissié J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys. J. 58 (1990) 1089-1098
4. Sersa G., Cemazar M., and Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 55 (1995) 3450-3455
5. Pendas S., Jaroszeski M.J., Gilbert R., Hyacinthe M., Dang V., Hickey J., Pottinger C., Illingworth P., and Heller R. Direct delivery of chemotherapeutic agents for the treatment of Hepatomas and sarcomas in rat models. Radiol. Oncol. 32 (1998) 53-64
6. Mir L.M., Tounekti O., and Orlowski S. Bleomycin: revival of an old drug. Gen. Pharmacol. 27 (1996) 745-748
7. Kranjc S., Cemazar M., Grosel A., Scancar J., and Sersa G. Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res. 23 (2003) 275-282
8. Kranjc S., Cemazar M., Grosel A., Sentjurc M., and Sersa G. Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer 5 (2005) 115
9. Alessio E., Mestroni G., Bergamo A., and Sava G. Ruthenium anticancer drugs. In: Siegl H. (Ed). Metal ions in Biological Systems, Metal Complexes in Tumor Diagnosis and as Anticancer Agents (2004), Marcel Dekker, New York 323-351 (0)
10. In: Keppler B.K. (Ed). Metal Complexes in Cancer Chemotherapy (1993), Wiley-VCH Verlag GmbH, Weinheim
11. Galanski M., Arion V.B., Jakupec M.A., and Keppler B.K. Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des. 25 (2003) 2078-2089
12. Sava G., Alessio E., Bergamo A., and Mestroni G. Sulfoxide ruthenium complexes: non-toxic tool for the selective treatment of solid tumour metastases. In: Sadler P.J. (Ed). Metallopharmaceuticals I: DNA Interactions (1999), Springer, Berlin 154-169
13. Alessio E., Mestroni G., Bergamo A., and Sava G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem. 4 (2004) 1525-1535
14. Rademaker-Lakhai J.M., van den Bongard D., Pluim D., Beijnen J.H., and Schellens J.H. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10 (2004) 3717-3727
15. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M., and Boccarelli A. Water-soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmaceutical properties. Met.-Based Drug. 1 (1994) 41-63
16. 4 (DMSO) (Ind)] with apotransferrin: a spectroscopic study. Met.-Based Drug. 3 (1996) 1-63
17. Messori L., Orioli P., Vullo D., Enzo A., and Iengo E. A spectroscopic study of the reaction of NAMI-A, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin. Eur. J. Biochem. 267 (2000) 1206-1213
18. Dyson P.J., and Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 16 (2006) 1929-1933
19. Frausin F., Cocchietto M., Bergamo A., Scarcia V., Furlani A., and Sava G. Tumor cell uptake of metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother. Pharmacol. 50 (2002) 405-411
20. Gava B., Zorzet S., Spessotto P., Cocchietto M., and Sava G. Inhibition of B16 Melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J. Pharmacol. Exp. Ther. 317 (2006) 284-291
21. G. Mestroni, E. Alessio, G. Sava, New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents, International Patent PCT C 07F 15/00, A61K 31/28, WO 98/00431.
22. Kotnik T., Macek-Lebar A., Miklavcic D., and Mir L.M. Evaluation of cell membrane electropermeabilization by means of a nonpermeant cytotoxic agent. BioTechniques 28 (2000) 921-926
23. Kanduser M., Sentjurc M., and Miklavcic D. Cell membrane fluidity related to electroporation and resealing. Eur. Biophys. J. 35 (2006) 196-204
24. Pluim D., van Waardenbur R.C., Beijnen J.H., and Schellens J.H. Cytotoxicity of the organic ruthenium anticancer drug NAMI-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother. Pharmacol. 54 (2004) 71-78
25. Bergamo A., Messori L., Piccioli F., Cocchietto M., and Sava G. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest. New Drugs 21 (2003) 401-411
26. Bergamo A., Gava B., Alessio E., Mestroni G., Serli B., Cocchietto M., Zorzet S., and Sava G. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int. J. Oncol. 21 (2002) 1331-1338